Literature DB >> 8905344

Inhibition of KATP channel activity by troglitazone in CRI-G1 insulin-secreting cells.

K Lee1, T Ibbotson, P J Richardson, P R Boden.   

Abstract

Patch-clamp recording techniques were used to examine the effect of troglitazone on KATP channel activity in Cambridge rat insulinoma-G1 (CRI-G1) insulin-secreting cells. In both inside-out and outside-out patch recordings, bath application of troglitazone reduced KATP channel activity. This inhibition was independent of the membrane voltage and was poorly reversible. In whole-cell studies, troglitazone inhibited KATP channel currents with an IC50 of 697 +/- 92 nM and an associated Hill coefficient of 1.2 +/- 0.2. In current clamp recordings 10 microM troglitazone depolarised the CRI-G1 cell membrane by 36.8 +/- 3.9 mV with a concomitant decrease in membrane conductance. However, in contrast to the rapid depolarisation produced by tolbutamide, the effects of troglitazone developed more slowly, usually taking 15-20 min to develop.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8905344     DOI: 10.1016/0014-2999(96)00619-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

Review 1.  PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty.

Authors:  Janice V Huang; Clifford R Greyson; Gregory G Schwartz
Journal:  J Lipid Res       Date:  2012-06-08       Impact factor: 5.922

2.  Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs.

Authors:  Ya Xu; Li Lu; Clifford Greyson; Jenny Lee; Michael Gen; Koichiro Kinugawa; Carlin S Long; Gregory G Schwartz
Journal:  Diabetes       Date:  2003-05       Impact factor: 9.461

3.  Sensitivity of Kir6.2-SUR1 currents, in the absence and presence of sodium azide, to the K(ATP) channel inhibitors, ciclazindol and englitazone.

Authors:  N G McKay; J M Kinsella; C M Campbell; M L Ashford
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

Review 4.  Kv1.3: a potential pharmacological target for diabetes.

Authors:  Bok Hee Choi; Sang June Hahn
Journal:  Acta Pharmacol Sin       Date:  2010-08-16       Impact factor: 6.150

5.  Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells.

Authors:  M Asano; T Nakajima; K Iwasawa; T Morita; F Nakamura; H Imuta; K Chisaki; N Yamada; M Omata; Y Okuda
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

6.  Serine-385 phosphorylation of inwardly rectifying K+ channel subunit (Kir6.2) by AMP-dependent protein kinase plays a key role in rosiglitazone-induced closure of the K(ATP) channel and insulin secretion in rats.

Authors:  T-J Chang; W-P Chen; C Yang; P-H Lu; Y-C Liang; M-J Su; S-C Lee; L-M Chuang
Journal:  Diabetologia       Date:  2009-04-09       Impact factor: 10.122

7.  Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs.

Authors:  L Lu; M J Reiter; Y Xu; A Chicco; C R Greyson; G G Schwartz
Journal:  Diabetologia       Date:  2008-02-05       Impact factor: 10.122

8.  Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery.

Authors:  Radda Rusinova; Karl F Herold; R Lea Sanford; Denise V Greathouse; Hugh C Hemmings; Olaf S Andersen
Journal:  J Gen Physiol       Date:  2011-08       Impact factor: 4.086

9.  Lipophilicity predicts the ability of nonsulphonylurea drugs to block pancreatic beta-cell KATP channels and stimulate insulin secretion; statins as a test case.

Authors:  Joana Real; Caroline Miranda; Charlotta S Olofsson; Paul A Smith
Journal:  Endocrinol Diabetes Metab       Date:  2018-03-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.